CLINICAL TRIALS PROFILE FOR ANTITHROMBIN III (HUMAN)
✉ Email this page to a colleague
All Clinical Trials for antithrombin iii (human)
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00174902 ↗ | The Effect of Beta-Blockers and Aspirin on Hemostasis and Endothelial Function After Acute Mental Stress | Unknown status | Swiss National Science Foundation | Phase 1/Phase 2 | 2003-10-01 | This randomized double-blinded controlled trial uses a factorial design to investigate whether application of beta-blockers (inderal 80 mg) or aspirin (100 mg) or a combination thereof has an effect on the activation of the hemostatic system, the platelets and the endothelium in response to acute mental stress. Specifically we test the hypothesis that inderal attenuates the activation of the hemostatic system as compared to placebo. The second hypothesis is that aspirin attenuates the activation of platelets as compared to placebo. Subjects will be randomly allocated to either of the four following study arms: placebo - inderal - aspirin - inderal plus aspirin. Subjects will receive the study medication for five days prior to the mental stress. The acute mental stress consists of a public speaking session of 10 min duration immediately followed by a mental arithmetic test of 5 min duration. Blood will be collected prior to the stress, immediately thereafter, at 45 min at at 1 hour and 45 min. |
| NCT00174902 ↗ | The Effect of Beta-Blockers and Aspirin on Hemostasis and Endothelial Function After Acute Mental Stress | Unknown status | Swiss Federal Institute of Technology | Phase 1/Phase 2 | 2003-10-01 | This randomized double-blinded controlled trial uses a factorial design to investigate whether application of beta-blockers (inderal 80 mg) or aspirin (100 mg) or a combination thereof has an effect on the activation of the hemostatic system, the platelets and the endothelium in response to acute mental stress. Specifically we test the hypothesis that inderal attenuates the activation of the hemostatic system as compared to placebo. The second hypothesis is that aspirin attenuates the activation of platelets as compared to placebo. Subjects will be randomly allocated to either of the four following study arms: placebo - inderal - aspirin - inderal plus aspirin. Subjects will receive the study medication for five days prior to the mental stress. The acute mental stress consists of a public speaking session of 10 min duration immediately followed by a mental arithmetic test of 5 min duration. Blood will be collected prior to the stress, immediately thereafter, at 45 min at at 1 hour and 45 min. |
| NCT00262054 ↗ | Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3) | Completed | Deutsches Herzzentrum Muenchen | Phase 4 | 2005-11-01 | The purpose of this study is to determine whether bivalirudin given during PCI is associated with better outcomes compared to un-fractionated heparin. |
| NCT00293501 ↗ | Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery | Unknown status | National Cancer Institute (NCI) | Phase 1/Phase 2 | 2005-12-01 | RATIONALE: Tinzaparin may stop the growth of kidney cancer by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects of tinzaparin and to see how well it works in treating patients with metastatic kidney cancer that cannot be removed by surgery. |
| NCT00293501 ↗ | Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery | Unknown status | University of Vermont | Phase 1/Phase 2 | 2005-12-01 | RATIONALE: Tinzaparin may stop the growth of kidney cancer by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects of tinzaparin and to see how well it works in treating patients with metastatic kidney cancer that cannot be removed by surgery. |
| NCT00319228 ↗ | Safety, Pharmacokinetics and Efficacy of an AT-III Concentrate. | Active, not recruiting | Grifols Biologicals Inc. | Phase 2/Phase 3 | 2006-01-01 | To assess the safety, pharmacokinetics and efficacy of a plasma-derived AT-III concentrate in the treatment of subjects with congenital AT-III deficiency. |
| NCT00319228 ↗ | Safety, Pharmacokinetics and Efficacy of an AT-III Concentrate. | Active, not recruiting | Grifols Biologicals, LLC | Phase 2/Phase 3 | 2006-01-01 | To assess the safety, pharmacokinetics and efficacy of a plasma-derived AT-III concentrate in the treatment of subjects with congenital AT-III deficiency. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for antithrombin iii (human)
Condition Name
Clinical Trial Locations for antithrombin iii (human)
Trials by Country
Clinical Trial Progress for antithrombin iii (human)
Clinical Trial Phase
Clinical Trial Sponsors for antithrombin iii (human)
Sponsor Name
